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23       ABSTRACT 
 
24 
 
25       We hypothesized that pH-responsive carboxymethylated kappa-carrageenan microparticles 
 
26       could protect entrapped oral insulin from acidic and proteolytic degradation in the 
 
27       gastrointestinal tract. The objectives were, therefore, to prepare and characterize insulin 
 
28       entrapped in lectin-functionalized carboxymethylated kappa-carrageenan microparticles and 
 
29       to evaluate their therapeutic efficacy in vitro and in vivo. The encapsulation of insulin was 
 
30       performed using an ionic gelation technique and was optimized to give an encapsulation 
 
31       efficiency of 94.2 ± 2.6% and a drug-loading capacity of 13.5 ± 0.4%. The microparticles 
 
32       were further surface lectin-functionalized for improved intestinal mucoadhesiveness. The oral 
 
33       administration of insulin entrapped in the microparticles led to a prolonged duration of the 
 
34       hypoglycemic effect, of up to 12–24 h, in diabetic rats. From the release profile and the low 
 
35       toxicity of the microparticles, it can be concluded that these lectin-functionalized 
 
36       carboxymethylated kappa-carrageenan microparticles have the potential to be developed into 
 
37       an oral insulin delivery system. 
 
38 
 
39       Keywords: Carrageenan; Insulin; Lectin; Microparticles; Oral delivery
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40       1. Introduction 
 
41 
 
42                     The current administration of peptide-based drugs, such as insulin, is predominately 
 
43       via the parenteral route, which has a number of disadvantages. These include discomfort due 
 
44       to repeated and prolonged dosage regimes, high variation in bioavailability and a non- 
 
45       physiological delivery pattern (Takei & Kasatani, 2004). These issues have brought about an 
 
46       increased effort to develop alternative delivery systems (Pillai & Panchangnula, 2001).  The 
 
47       recent introduction of an inhaled delivery system for insulin was short-lived and resulted in 
 
48       the withdrawal of the product from the market by pharmaceutical companies (Opar, 2008). 
 
49       Recently, a pre-clinical study of an oral insulin formulation for type-2 diabetic patients 
 
50       showed promising results (Kapitza et al., 2010). Therefore, the oral delivery of insulin still 
 
51       remains an attractive alternative delivery route. Some advantages of the oral delivery system 
 
52       include the elimination of the risk of needle infection, increased patient compliance and a 
 
53       lower cost of therapy (Heller, Kozlovski & Kurtzhals, 2007; Russell-Jones, 2004). It is also 
 
54       physiologically more desirable, because orally administrated insulin mimics the physiological 
 
55       pathway that undergoes the first hepatic bypass and produces a similar effect as pancreas- 
 
56       secreted insulin (Sarmento, Ribeiro, Veiga, Ferreira & Neufeld, 2007).  However, peptide- 
 
57       based drugs, such as insulin, are difficult to deliver orally due to enzymatic degradation and 
 
58       their inability to transverse the biological barriers of the gastrointestinal tract. Therefore, 
 
59       recent research has focused on protecting the drug from degradation using drug carriers that 
 
60       include enzyme inhibitors and improving absorption via the incorporation of permeability 
 
61       enhancers (Khafagy, Morishita, Onuki & Takayama, 2007). 
 
 
62                     Among the drug carriers investigated, carriers derived from natural polysaccharides 
 
63       have commanded particular interest due to their biodegradability, biocompatibility,
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64       hydrophilicity and protective properties (Liu, Jiao, Wang, Zhou & Zhang, 2008). Natural 
 
65       polysaccharides such as alginates and chitosan were extensively used because of their 
 
66       favorable characteristics for drug entrapment (Sarmento, Ferreira, Jorgensen & van de Weert, 
 
67       2007). The advantage of using such hydrogels is the ease of performing water-based 
 
68       ionotropic gelation during the process of drug encapsulation. Moreover, it has been shown 
 
69       that such an ionotropic gelation process preserves the bioactive conformation of the insulin 
 
70       drug (Martins, Sarmento, Souto & Ferreira, 2007). 
 
 
71                     A recent report shows that the incorporation of dextran sulfate in the encapsulation of 
 
72       insulin with alginate and chitosan polymer mixtures improved the protection of insulin in an 
 
73       acidic in vitro acidic environment. The enhanced protection is attributed to the ionic 
 
74       interaction between the sulfate groups in the dextran sulfate with the amino acid residues in 
 
75       the insulin molecules (Martins, Sarmento, Souto & Ferreira, 2007). Such a phenomenon was 
 
76       previously noted when protein-polyions complexation reduced the rate of protein escape due 
 
77       to enhanced electrostatic interactions (Kamiya & Klibanov, 2003). Both Tiyaboonchai, 
 
78       Woiszwillo, Sims & Middaugh (2003) and Sarmento, Ribeiro, Veiga, Ferreira & Neufeld 
 
79       (2007) highlighted the prolonged glycemic effect and the promotion of sustained insulin 
 
80       availability in vivo with the inclusion of dextran sulfate as a physical mixture in their carrier 
 
81       systems. 
 
 
82                     To assist drug absorption in the intestinal region, mucoadhesive polymers have been 
 
83       adopted (Chowdary & Rao, 2004; Andrews, Laverty & Jones, 2009). These mucoadhesive 
 
84       particles are able to prolong the residence time at the site of release, initiate contact with the 
 
85       intestinal barrier and create a drug concentration gradient that promotes the penetration of the 
 
86       drug through the intestinal membrane (Smart, 2005). Naturally derived mucoadhesive 
 
87       polymers, such as lectin, show promising mucoadhesive properties, particularly at the
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88       intestinal site (Clark, Hirst & Jepson, 2000; Bies, Lehr & Woodley, 2004), and they may be 
 
89       exploited for an intestinal-targeted delivery system (Lehr, 2000; Peppas & Kavimandan, 
 
90       2006). Among the different types of lectin, wheat germ agglutinin (WGA), a glycoprotein 
 
91       from Triticum vulgare, binds to N-acetyl-D-glucosamine and sialic acid moieties, which are 
 
92       mainly found on both M-cells and regular intestinal absorptive cells in the intestine (Yin et 
 
93       al., 2007), and improves drug absorption for oral insulin delivery (Zhang et al., 2006). 
 
 
94                     Recently, we reported a new pH-responsive carboxymethylated kappa-carrageenan 
 
95       developed using a modeling technique for the intestinal-targeted delivery of macromolecules. 
 
96       The in vitro dissolution study indicated that the model molecule, fluorescein isothiocyanate- 
 
97       labeled dextran entrapped in carboxymethylated kappa-carrageenan microparticles, showed 
 
98       minimal release in an acidic environment (simulated gastric fluid; SGF) but showed favorable 
 
99       release in simulated intestinal fluid (SIF), suggesting its potential as a carrier for the oral 
100 delivery of hydrophilic macromolecules to the intestinal tract (Leong et al., 2011).
 
101 Unlike earlier studies that used dextran sulfate in the form of a physical mixture
102 incorporated into the delivery systems, the carboxymethylated kappa-carrageenan used here
103 contains naturally occurring sulfate groups in the polymer chain. It is conceivable that these
104 covalently linked sulfate groups improve the encapsulation efficiency, drug-loading capacity
105 and the stability of insulin entrapped in the carrageenan microparticles via ionic interactions
106 between the carrageenan sulfate groups and the amino groups of the amino acid residues in
107 insulin. This phenomenon is also likely to inhibit the release of insulin from the
108 microparticles and, together with lectin functionalization of the microparticles, is likely to
109 make it behave as a prolonged sustained release system in the intestinal region. Herein, we
110 report our findings on the use of lectin-functionalized carboxymethylated kappa-carrageenan
111 microparticles as an alternative and improved carrier for the oral delivery of insulin.
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112 
 
113 
 
114 
2. Materials and methods
115 
 
116 
2.1. Materials
 
117 Kappa-carrageenan (batch no.: 405301) was supplied by the Marine Science Co., Ltd.
118 (Tokyo, Japan). Human recombinant insulin, lectin from Triticum vulgaris (WGA), 200 mM
119 L-glutamine, fetal bovine serum (FBS), 0.25% trypsin-EDTA and phosphate buffered saline
120 (pH 7.4) tablets were purchased from Sigma–Aldrich (St. Louis, MO, USA). Potassium
121 chloride, sodium hydroxide, potassium dihydrogen orthophosphate, 37% fuming
122 hydrochloric acid and acetonitrile were supplied by Fisher Scientific UK, Ltd.
123 (Loughborough, Leicestershire, UK). Glutaraldehyde 25% v/v, orthophosphoric acid, sodium
124 acetate salt and Chromolith Performance RP-18e HPLC columns (4.6 x 100 mm) were from
125 Merck KGaA (Darmstadt, Germany). Syringes (1 mL) and needles with diameters of 25G
126 (0.50 x 16 mm), 26G (0.45 x 13 mm) and 27G (0.40 x 13 mm) were supplied by Terumo
127 (Laguna, Philippines). Dulbecco’s modified Eagle’s medium (DMEM), 100 mM non-
128 essential amino acid, Hank’s Balanced Salt Solution (HBSS), 50 g/mL gentamycin and 2.5
129 g/mL amphotericin B were purchased from the Invitrogen Corporation (Carlsbad, CA,
130 USA). The MTS assay kit [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
131 sulfophenyl)-2H-tetrazolium, inner salt] was supplied by Promega (Madison, WI, USA), and
132 
 
 
133 
the LDH (lactate dehydrogenase) assay kit was from Roche (Mannheim, Germany).
 
134 2.2. Methods
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135 
 
136 
 
 
137 
2.2.1. Synthesis and characterization of carboxymethylated kappa-carrageenan
 
138 Carboxymethylated kappa-carrageenan was prepared by a previously described
139 method (Leong et al., 2011). In brief, 5 g of powdered kappa-carrageenan was suspended in
140 100 mL of 2-propanol and stirred for 30 min at room temperature. Next, 5 mL of 16 N
141 sodium hydroxide solution was added at a rate of 1 mL per 15 min with continuous stirring at
142 room temperature. Monochloroacetic acid (5.3 g) was then added portionwise to the reaction
143 mixture over a period of 20 min. The reaction mixture was heated to 50 °C with continuous
144 stirring for 4 h to drive the reaction process to completion. The product was recovered
145 through vacuum filtration and washed alternately with 50 mL of ethanol-water (4:1) and 50
146 mL of ethanol three times. The modified carrageenan was oven dried at 70 °C overnight and
147 powdered in a glass mortar.
 
148 The degree of carboxymethylation on the modified kappa-carrageenan was
149 determined using a NMR protocol as described previously (Leong et al., 2011). The swelling
150 and gelling properties of the modified carrageenan in simulated gastric fluid (SGF) (pH 1.2)
151 and simulated intestinal fluid (SIF) (pH 7.4) were measured using a previously described
152 method (Leong et al., 2011).
 
153 Molecular weight was measured using size-exclusion liquid chromatography
154 (Spichtig & Austin, 2008). Briefly, the system consisted of a Waters 2690 solvent delivery
155 module, a Waters 2410 refractive index detector (Waters Co., Milford, MA, USA), two
156 coupled Waters Ultrahydrogel Linear columns (7.8 mm x 300 mm) and a Waters millennium
157 v3.02 workstation. The mobile phase was 0.1 M lithium nitrate with a flow rate of 0.6
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158 mL/min. A sample volume of 100 µL was injected into the system at 10 mg/mL. Standard
159 solutions of polyethylene oxide (24.2–932 kDa) (Showa Denko, Kanagawa, Japan) at 10
160 mg/mL were analyzed, and the logarithm of the molecular weight of the standard versus
161 
 
162 
retention time was used to construct a standard curve for the estimation of molecular weight 
 
(linearity, R
2 
= 0.993).
 
163 Sulfate content was determined using ion chromatography. Briefly, a 1 mg sample
164 was hydrolyzed in 1 mL of 2 M trifluroacetic acid (TFA) for 1 h in a 120 ºC oil bath. The
165 hydrolyzed sample was allowed to cool, and 2 mL of deionized water was added and mixed.
166 It was then centrifuged at 5,000 rpm, and 50 µL of the sample was analyzed using an ICS
167 1600 ion-chromatography system equipped with a conductivity detector (Dionex
168 Corporation, Sunnyvale, CA, USA). The anions were separated on a Waters IC-Pak Anion
169 (4.6 x 150 mm) column (Waters Co., USA) with a mobile phase of borate-gluconate buffer
170 (pH 8.5) and flow rate of 2 mL/min. The sulfate content was expressed as a weight
171 
 
 
172 
percentage of the analyzed sample (% w/w).
 
173 
 
 
174 
2.2.2. Preparation of insulin-loaded microparticles
 
175 Insulin-loaded microparticles were prepared using an ionotropic gelation process
176 (Sipahigil & Dortunç, 2001). For this purpose, 125–175 mg powdered carboxymethylated
177 kappa-carrageenan was dissolved in 1 mL of pH-adjusted (pH 4.0–7.0) deionized water with
178 0.3 M sodium acetate buffer (pH 4.0). To this solution, 1 mL of human insulin (10–30
179 mg/mL) was added and mixed thoroughly to form a viscous dispersion. The resulting
180 dispersion was then loaded into a 1 mL syringe and extruded dropwise through a needle of
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181 varying internal diameter (0.4–0.5 mm) into 20 mL of 1.5 M potassium chloride-HCl solution
182 (pH 1.2) with constant stirring (50 rpm) under a constant stream of air blown perpendicular to
183 the tip of the needle. The insulin-loaded microparticles were then collected by decantation
184 
 
 
185 
and dried in a dessicator overnight at 4 ºC.
 
186 
 
 
187 
2.2.3. Preparation of insulin-loaded lectin surface-conjugated microparticles
 
188 To functionalize the surface of the insulin microparticles, the microparticles were first
189 surface activated with polyglutaraldehyde (Tanriseven & Ölçer, 2008) followed by
190 conjugation to lectin (Montisci, Giovannuci, Duchêne & Ponchel, 2001). Briefly, 0.15 mL of
191 1 N sodium hydroxide was added to 5 mL of 25% v/v glutaraldehyde solution to give a pH of
192 10.5, and the mixture was shaken at 200 rpm for 30 min. Then, 0.15 mL of 1 N hydrochloric
193 acid was added to the reaction mixture to neutralize and stop the polymerization reaction to
194 give a polyglutaraldehyde solution. Then, 0.53 mL of the polyglutaraldehyde solution was
195 acidified with 0.25 mL of 1 M sulfuric acid, brought up to 1 mL with deionized water to give
196 12.5% (v/v) and then further diluted to 0.1–5.0% v/v polyglutaraldehyde using deionized
197 water as needed.
 
198 The freshly collected insulin-loaded microparticles from Section 2.2.2 were soaked in
199 10 mL of polyglutaraldehyde solution (0.1–5.0% v/v) for 1 h. Then, the microparticles were
200 rinsed four successive times with 5 mL of 1.5 M potassium chloride-HCl solution (pH 1.2) to
201 remove excess crosslinking reagent, followed by washing with deionized water (5 mL).
 
202 The surface-activated insulin-loaded microparticles were immersed in a lectin
203 solution (0.25–1.25 mg/mL PBS, pH 7.4) for 30 min. The lectin surface-conjugated
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204 microparticles were washed with 5 mL of 1.5 M potassium chloride-HCl (pH 1.2) and
205 
 
 
206 
deionized water (5 mL). The beads were then dried in a dessicator overnight at 4 ºC.
 
207 
 
 
208 
2.2.4. Determination of insulin encapsulation efficiency and insulin load
 
209 To determine the encapsulation efficiency and the total insulin load of the obtained
210 microparticles from Section 2.2.2, an indirect method to measure the insulin content in the
211 1.5 M potassium chloride-HCl solution (hardening solution) using an established HPLC
212 protocol was performed (Deeb, Preu & Wätzig, 2007). The system consisted of a Waters
213 2690 solvent delivery module, a Waters 996 PDA (Waters Co., Milford, MA, USA), two
214 coupled Chromolith Performance RP-18e columns (4.6 mm x 100 mm, Merck, Darmstadt,
215 Germany) and a Waters millennium v3.02 workstation. The composition of the mobile phase
216 was 0.2 M sodium sulfate adjusted to pH 2.3 with orthophosphoric acid and acetonitrile
217 (76.5:23.5) with a flow rate of 1 mL/min. The sample volume was 50 L and it was
218 monitored at 214 nm. Standard solutions of human insulin (0.01–1.00 mg/mL) (Fig. 1) were
219 analyzed and the AUC values were used to construct the standard curve for the estimation of
220 insulin content in the hardening solution. The encapsulation efficiency and drug-loading
221 
 
 
222 
capacity were calculated as follows:
 
223 Encapsulation efficiency (EE) = {[Insulin added (mg) – Free insulin in supernatant (mg)] /
224 
 
 
225 
Insulin added (mg)} x 100%
Page 11 of 43 
 
226 Drug-loading capacity (DLC) = {[Insulin added (mg) – Free insulin in supernatant (mg)] /
227 
 
 
228 
Polymer used (mg)} x 100%
 
229 
 
230 
The HPLC method was validated for limit of detection (5 µg insulin/mL), linearity 
 
(R
2 
= 0.992 ± 0.007 (mean ± SD; n = 6)) and repeatability at 7.5 µg/mL (low), 75 µg/mL
231 (medium) and 750 µg/mL (high concentration) (n = 6) for both intraday and interday runs.
232 The precision of the analysis, as measured by the coefficient of variation (CV) and accuracy,
233 was within an acceptable range of less than ±10%. There were no matrix effects of the
234 
 
 
235 
different media (SGF and SIF) employed.
 
236 
 
 
237 
2.2.5. Determination of degree of surface lectin conjugation
 
238 To determine the amount of lectin conjugated to the surface of the microparticles, an
239 indirect HPLC method to measure the unreacted lectin in Section 2.2.3 was adopted. This
240 procedure was performed in parallel to the determination of the insulin encapsulation
241 efficiency and insulin load described in Section 2.2.4. The HPLC system and conditions
242 described in Section 2.2.4 were used. Standard solutions of lectin (0.005–1.00 mg/mL) (Fig.
243 1) were analyzed, and the AUC values were used to construct the standard curve for the
244 estimation of unreacted lectin in the hardening solution (section 2.2.3). The amount of lectin
245 
 
 
246 
conjugated to the insulin-loaded microparticles was calculated as follows:
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247 Surface conjugated lectin = {[Lectin added (mg) – Free lectin in supernatant (mg)] / Lectin
248 
 
 
249 
added (mg)} x 100%
 
250 
 
251 
This HPLC method was validated for the limit of detection (1 µg lectin/mL), linearity 
 
(R
2 
= 0.994 ± 0.003 (mean ± SD; n = 6)) and repeatability at 7.5 µg/mL (low), 75 µg/mL
252 (medium) and 750 µg/mL (high concentration) (n = 6) for both intraday and interday runs.
253 The precision of the analysis, as measured by the coefficient of variation (CV) and accuracy,
254 was within an acceptable range of less than ±10%. There were no matrix effects of the
255 
 
 
256 
different media (SGF and SIF) employed.
 
257 
 
 
258 
2.2.6. Mucoadhesive determination
 
259 Mucoadhesive determination of surface lectin-conjugated microparticles was
260 performed using the everted sac method (Santos et al., 1999). Male Sprague-Dawley rats
261 (200–270 g) were sacrificed under ether, and intestinal segments were obtained. The
262 intestinal segments were washed with 10 mL of ice-cold phosphate buffer saline (pH 7.2)
263 containing 200 mg/dL glucose (PBSG). The intestines were cut into 6-cm lengths, everted
264 using a stainless steel rod and lightly washed with PBSG to remove remaining impurities.
265 One end of the intestine was sealed, and 1.5 mL of PBSG was added and finally sealed to
266 form an intestinal sac. The intestinal sac was incubated in 5 mL of PBSG containing 60 mg
267 lectin-functionalized microparticles in a 37 °C water bath and agitated at 100 rpm for 30 min.
268 After incubation, the intestinal sac with bound microparticles on the outer surface was
269 carefully removed and the PBSG with unbound microparticles was centrifuged at 5000 rpm
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270 for 30 min. The supernatant was discarded and the remaining unbound microparticles were
271 freeze-dried until they reached a constant weight (three days). The mucoadhesiveness of the
272 microparticles was determined by subtracting the initial weight of microparticles from the
273 
 
 
274 
weight of the unbound microparticles and expressed as the percent binding.
 
275 
 
 
276 
2.2.7. Microparticle size and surface characteristics determination
 
277 The diameters of freshly prepared (wet) and dried microparticles were estimated using
278 a microscope (CX31, Olympus Optical Co., Ltd., Tokyo, Japan) with an eyepiece linear
279 graticule. For the determination of the size and surface characteristics of the lectin-
280 functionalized and non-functionalized microparticles fabricated with the optimized
281 parameters, the dried microparticles were placed on double-sided carbon adhesive tape
282 mounted on an aluminum stab, and they were assessed using a field emission scanning
283 electron microscope (Quanta 200 FESEM, FEI, Oregon, USA) in a low-vacuum mode with
284 
 
 
285 
50, 2,000, 8,000 and 50,000x magnifications.
 
286 
 
 
287 
2.3. In vitro studies
 
288 
 
 
289 
2.3.1. In vitro insulin release kinetics
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290 The study was performed based on a modified version of a previously reported
291 protocol (Leong et al., 2011). In short, dried insulin-loaded microparticles (200 mg) were
292 placed in 20 mL of simulated gastric fluid (SGF) (pH 1.2) with stirring (100 rpm) at 37 °C for
293 2 h. Then 1-mL aliquots of the solution were removed at set time intervals and replaced with
294 fresh medium, and the dilution effect was normalized mathematically. After 2 h, the SGF was
295 carefully removed, replaced and incubated with 20 mL of SIF (pH 7.4) with stirring at 37 °C
296 for 8 h. One-milliliter aliquots of the solution were removed at set time intervals and replaced
297 with fresh medium. The level of insulin released from the microparticles into the SGF (pH
298 1.2) and SIF (pH 7.4) was determined by HPLC, as described in section 2.2.4. The biological
299 activity of the released insulin at the final 10-h time point was measured using a
300 commercially available human insulin ELISA kit (Mercodia AB, Uppsala, Sweden). Briefly,
301 25 L of the samples and insulin standards was added to the appropriate wells of a 96-well
302 microplate in triplicate, followed by the addition of 100 L of enzyme conjugate and
303 incubation at room temperature for 60 min. The reaction mixtures were then removed from
304 the wells and washed six times with washing buffer; 200 L of tetramethylbenzidine (TMB)
305 substrate was then added and incubated for 15 min. Fifty microliters of stop solution was
306 added, and the absorbance was measured at 450 nm using a microplate reader (Infinity M200,
307 Tecan, Mannedorf, Switzerland). The insulin concentrations of the samples were obtained
308 from the absorbance readings of the standard concentration curve.
 
309 Insulin profiles from the encapsulated microparticles were fitted into the Power law
310 equation (Lin & Metters, 2006; Siepmann & Peppas, 2001) to calculate n and determine the
311 
 
 
312 
insulin release kinetics:
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313 
 
 
314 
Mt / M∞ = kt
n
 
315 where Mt is the amount of insulin released up to a specified time, t; M∞ is the final amount of
316 insulin released; k is the structural/geometric constant for a particular system; t is the
317 sampling time and n represents the release exponent of the release mechanism. Statistical
318 analyses were carried out using Student’s paired t-test, where p < 0.05 was selected as the
319 
 
 
320 
criterion of significance.
 
321 
 
 
322 
2.3.2. Cell culture
 
323 Human colorectal carcinoma cells (Caco-2) from American Type Culture Collection
324 (ATCC) were growth as monolayers in high glucose (4.5 g/L) Dulbecco’s modified Eagle’s
325 medium (DMEM) supplemented with 1% non-essential amino acids, 2 mM L-glutamine, 10%
326 fetal bovine serum (FBS), 50 µg/mL gentamycin and 2.5 µg/mL amphotericin B. Cells were
327 
 
 
328 
cultured at 37 ºC in a humid atmosphere of 5% CO2.
 
329 
 
 
330 
2.3.3. Cell viability assays
 
331 Caco-2 cells (passage no.: 51–59; 50,000 (MTS assay) or 25,000 (LDH assay) cells
332 per well in 96-well microplates seeded 24 h prior treatment) were incubated for 1–3 days
333 with microparticles at final concentrations of 0.5–20 mg/mL. Positive controls consisted of 5-
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334 fluorouracil (0.005       500 g/mL) and Triton-X (1% v/v). Cytotoxicity was evaluated by
335 measurements of the cell viability (growth inhibition) and cell death (cellular membrane
336 damage), using standard MTS and LDH release assays, respectively (Jos et al., 2009). The
337 
 
 
338 
percent of cell viability and cell death were calculated as follows:
 
339 
 
 
340 
Cell viability (%) = Asample / Acontrol x 100%
 
341 where Asample is the absorbance measured after treatment with the sample, and Acontrol is the
342 
 
 
343 
absorbance measured for the untreated cells (negative control).
 
344 
 
 
345 
Cell death (%) = (Asample – Aspontaneous / ATriton-X – Aspontaneous) x 100%
 
346 where Asample is the absorbance measured after treatment with sample, Aspontaneous is the
347 absorbance measured without treatment and ATriton-X is the absorbance measured after
348 treatment with 1% (v/v) Triton-X.
 
349 Investigation of the cellular tight junction integrity was conducted by seeding cells at
350 280,000 cells per well on a 24-well polycarbonate Transwell filter insert microplate (Costar,
351 Corning Inc., New York, USA) as described previously (Simon et al., 2007). Cells were
352 grown on the membrane inserts (0.4 µm pore size) for 21 days. After 21 days, the initial
353 transepithelial electric resistance (TEER) was measured at room temperature with an
354 EVOM™ voltammeter (World Precision Instruments, Berlin, Germany) equipped with
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355 Endohm™ electrodes. Microparticles at concentrations of 0.5–20 mg/mL and control (culture
356 medium) were introduced and incubated at 37 ºC in a humid atmosphere of 5% CO2 for
357 various time intervals (0.5, 1, 2, 4, 8 and 16 h).  After the incubation periods, TEER
358 measurements were taken and changes in the cellular tight junctions were calculated as the
359 
 
 
360 
percent change relative to the initial resistance value.
 
361 
 
 
362 
2.4. In vivo study
 
363 
 
 
364 
2.4.1. Animals
 
365 Male Sprague-Dawley rats (220–270 g) were housed at 20–25 °C and 55 ± 5%
366 relative humidity with a 12-hour light-dark cycle. A standard pellet diet and water were
367 provided ad libitum during acclimatization. Experimental work was carried out at the Center
368 for Animal Studies, University Malaya Medical Center, Kuala Lumpur, Malaysia, in
369 accordance with institutional guidelines (animal ethics approval reference number:
370 
 
 
371 
FAR/008/12/2008/CLP(R)).
 
372 
 
 
373 
2.4.2. Glucose lowering effect and in vivo bioavailability
 
374 The procedure described earlier was adopted with minor modifications (Morishita et
375 al., 2006). Diabetes was induced in male Sprague-Dawley rats by intraperitoneal
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376 administration of 45 mg/kg of streptozocin in 0.1 M sodium citrate buffer (pH 4.0). After two
377 weeks, rats with fasting blood glucose levels above 300 mg/dL were randomly allocated into
378 nine groups of 6–8 rats in each.  The rats were fasted 12 h before and during the experimental
379 period, but water was provided ad libitum.
 
380 The microparticles were pre-packed in hard gelatin capsules (size 9, Qualicaps
®
381 capsule, Shionogi Qualicaps Co., Ltd., Nara, Japan) and administered orally at 25, 50 and 100
382 IU insulin/kg using a bulb-tipped gavage needle. Non-lectin surface-functionalized
383 microparticles were administered at 50 and 100 IU insulin/kg. Positive controls received
384 subcutaneous injection of 2 IU insulin/kg and the oral administration of insulin solution at
385 100 IU/kg. Negative controls received oral administration of capsules containing “empty”
386 microparticles or were untreated. Blood was collected from the tail vein immediately before
387 treatment and 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 and 36 h after administration. Blood glucose levels
388 were measured using an Accu-Check Active blood glucose meter (Roche, Mannheim,
389 Germany). The post-treatment blood glucose levels were expressed as the percentage of pre-
390 treatment blood glucose. For quantitative serum insulin determination, the blood samples
391 were centrifuged at 5000 rpm at 4 °C for 10 min, and the resulting serum was stored at -80 ºC
392 before analysis. The level of insulin in the serum was then measured using the ELISA method
393 described in section 2.3. The relative bioavailability of the oral formulations against the
394 
 
 
395 
subcutaneous administration of insulin was calculated as follows:
 
396 
 
 
397 
Relative bioavailability (BA) = [AUC(oral) x Dose (sc) / AUC (sc) x Dose (oral)] x 100%
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398 where AUC is the total area under the curve of the serum insulin concentration at time
399 
 
 
400 
intervals; oral represents oral formulation and sc represents subcutaneous administration.
 
401 
 
 
402 
2.5. Statistical analysis
 
403 Results were expressed as the mean ± SD (n = 6). Statistical significance was
404 determined by one-way ANOVA followed by the Bonferroni post hoc test (GraphPad Prism,
405 version 5.00, San Diego, California, USA). Differences were considered significant when P <
406 
 
 
407 
0.05.
 
408 
 
 
409 
3. Results and discussion
 
410 
 
 
411 
3.1. Synthesis and characterization of carboxymethylated kappa-carrageenan
 
412 
 
413 
Carboxymethylated kappa-carrageenan was synthesized from kappa-carrageenan and 
 
characterized. Briefly, 
1
H NMR and 
13
C NMR spectra of carboxymethylated kappa-
414 carrageenan were consistent with our earlier report (Leong et al., 2011). The degree of
415 carboxymethylation was 1.1413 ± 0.0283, the swelling ratios in SGF and SIF were 1.00 ±
416 0.01 and 1.23 ± 0.01, respectively, which were consistent with the parameters for the
417 optimum formulation (Leong et al., 2011). Size-exclusion liquid chromatography and ion
418 chromatography analyses showed that the molecular weights of native kappa-carrageenan
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419 and carboxymethylated kappa-carrageenan were 840 ± 15 and 762 ± 13 kDa (mean ± SD; n =
420 5), whereas the sulfate contents were 22.0 ± 0.8 and 18.4 ± 0.6% w/w (mean ± SD; n = 3),
421 respectively. These data suggest that the carboxymethylation conditions adopted caused only
422 
 
 
423 
minimal scissoring of the carrageenan backbone and reduction in sulfate groups.
 
424 
 
 
425 
3.2. Preparation of insulin-loaded microparticles
 
426 The encapsulation of insulin in microparticles was performed with different quantities
427 of carboxymethylated kappa-carrageenan (125–175 mg) and needle sizes (0.4–0.5 mm),
428 using 10 mg of insulin. A carboxymethylated kappa-carrageenan weight of 175 mg caused
429 blockage of both the 0.45- and 0.4-mm needles, whereas 150 mg blocked the needle size of
430 0.4 mm, and the microparticles could not be formed. The highest percentage of insulin
431 encapsulated in microparticles (74.8 ± 1.2%) was obtained from a polymer weight of 175 mg
432 using a 0.5-mm needle (Fig. 2A). At the fixed needle size (0.5 mm), the encapsulation
433 efficiency of insulin decreased with lower amounts of carboxymethylated kappa-carrageenan
434 even though the size of the microparticles remained unchanged. However, decreasing the
435 needle size from 0.5 to 0.4 mm for 125 mg of carboxymethylated kappa-carrageenan reduced
436 both the encapsulation efficiency and the microparticle size from 1.3 ± 0.2 mm to 0.7 ± 0.1
437 mm in diameter (Fig. 2B). Therefore, 175 mg of carboxymethylated kappa-carrageenan and a
438 needle size of 0.5 mm were used to prepare insulin-loaded microparticles.
 
439 Insulin is composed of 51 amino acid residues with both amino and carboxylic acid
440 side groups. These groups form a net negative or positive charge (isoelectric balance) for the
441 insulin molecule, depending on the pH of the environment. Above pH 5.4, insulin is
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442 negatively charged, whereas a net positive charge of 0.93 to 0.19 occurs at pH 4.8–5.2. At a
443 pH lower than 4.8, insulin has a net positive charge of more than 1 (Wintersteiner &
444 Abramson, 1932). The effect of pH on the encapsulation of insulin by carboxymethylated
445 kappa-carrageenan microparticles was studied by adding different volumes of a weak acid
446 buffer (0.3 M sodium acetate buffer) into the carrageenan-insulin mixture. The addition of 0.1
447 mL of acetate buffer shifted the pH to 5.0 ± 0.1, giving the insulin molecule a net positive
448 charge of less than 1. When 0.5 mL and 1.0 mL of acetate buffer were added, the pH was
449 reduced to 4.4 ± 0.2 and 4.0 ± 0.2, respectively. In these environments, the insulin molecules
450 have a net positive charge of more than 1 (Wintersteiner & Abramson, 1932). The findings
451 showed a significant encapsulation improvement (97.7 ± 2.2%) when insulin has a net
452 positive charge of less than 1 (Fig. 2C), which could be due to the favorable ionic interaction
453 between the positively charged amino groups of insulin and the permanently negatively
454 charged sulfate groups of carrageenan. If the insulin molecule assumed a net positive charge
455 higher than 1, then the encapsulation efficiency decreased (78.9 ± 5.2% and 82.2 ± 3.4%)
456 (Fig. 2C).
 
457 The drug-loading capacity of the microparticles was investigated by increasing the
458 amount of insulin (10–35 mg) in the insulin-carrageenan mixture. The encapsulation
459 efficiency showed a significant drop when 30 mg of insulin was loaded into the system.
460 Therefore, 25 mg was selected for the optimal drug load with an encapsulation efficiency of
461 94.2 ± 2.6%, and a drug-loading capacity of 13.5 ± 0.4% was achieved (Fig. 2D). These high
462 insulin-loaded microparticles possess several advantages, such as a smaller dosage form and
463 the ability to create a high drug-concentration gradient. This high drug-concentration gradient
464 serves as a driving force to assist the absorption of the drug across the intestinal barrier. The
465 findings showed an improved drug load compared to earlier reports on similar needle-based
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466 microparticle encapsulation techniques that had insulin-loading capacities of 2.48–3.00%
467 (Martins et. al., 2007), 2.00–2.86% (Ramkissoon-Ganorkar, Liu, Baudys & Kim, 1999) and
468 1.49–1.68% (Rekha & Sharma, 2009). Notably, the drug-loading capacity showed an increase
469 of 0.2–0.4% upon the incorporation of 0.5% (w/v) dextran sulfate into its formulation
470 (Martins, Sarmento, Souto & Ferreira, 2007). Such improvements were attributed to the ionic
471 interactions of the negatively charged sulfate and the amino acids of the insulin.  The
472 prepared carboxymethylated kappa-carrageenan polymer had permanent negatively charged
473 sulfate groups and also showed an improvement on drug-loading capacity. This result further
474 suggests that the presence of sulfate groups may prevent the premature leakage of insulin
475 from this microparticle system.
476 The lectin surface functionalization of insulin-loaded microparticles was performed
477 using polyglutaraldehyde as the crosslinker (Tanriseven & Ölçer, 2008). During the
478 activation step, polyglutaraldehyde is induced to selectively react with hydroxyl groups
479 present on the surface of the carrageenan microparticles (Machado, Lopes, Sousa & Airoldi,
480 2009). Between 0.1 to 0.6% (v/v), polyglutaraldehyde showed no significant difference
481 compared to the control in its ability to release insulin (Fig. 2E). However, at concentrations
482 greater than 0.6% (v/v) polyglutaraldehyde, the insulin release decreased. Thus, 0.6% (v/v)
483 polyglutaraldehyde was selected as the optimum concentration for surface activation of the
484 carrageenan microparticles. As the concentrations of lectin increased from 0.25 to 0.75
485 mg/mL, the percentage weight of the lectin surface-functionalized microparticles bound to rat
486 intestine increased from 54.6 to 82.0% (Fig. 2F). At higher concentrations of lectin, the
487 mucoadhesiveness remained at around 80–82%, whereas non-lectin-functionalized
488 microparticles showed a mucoadhesiveness of 49.6%. Thus, the optimized concentration of
489 lectin for surface functionalization was 0.75 mg/mL.
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490 Non-lectin-functionalized carrageenan microparticles were spherical in shape with an
491 average diameter of 1,304 ± 113 m (mean ± SD, n = 50) and a smooth surface at 50x
492 magnification, but they appeared crystalline-like under 8000x magnification (Fig. 3A & B).
493 Lectin-functionalized microparticles were less spherical, with a similar size (1,273 ± 201 µm)
494 but with a fibrous surface (Fig 3C & D). This clearly showed that lectin had been
495 successfully conjugated to the surface of the microparticles and assumed a strain-like fibrous
496 
 
 
497 
structure, which accounts for the improved adhesion to the intestinal wall.
 
498 
 
 
499 
3.3. In vitro studies
 
500 
 
 
501 
3.3.1. In vitro insulin release
 
502 The in vitro release of insulin from non-surface-functionalized and lectin surface-
503 functionalized carboxymethylated kappa-carrageenan microparticles was investigated to
504 simulate the transition of microparticles from the stomach to the intestinal region after oral
505 ingestion with 2 h in simulated gastric fluid (SGF) followed by 8 h in simulated intestinal
506 fluid (SIF) (Fig. 4). The release of insulin from non-lectin surface-functionalized
507 microparticles in SGF was minimal (4.2 ± 0.4%) during the first 2 h. Upon transferring to
508 SIF, the insulin was rapidly released within 10 h of the studied period. Complete insulin
509 release was observed at 10 h when analyzed using the HPLC method. With lectin surface-
510 functionalized microparticles, the release of insulin was further inhibited in SGF and SIF, and
511 full release was observed at 10 h.
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512 To ascertain the biological activity of the released insulin in SIF (pH 7.4), the samples
513 collected at 10 h were analyzed using ELISA. The results were in good accordance with those
514 measured using HPLC (Fig. 4), giving values of 11.1 ± 5.0% higher for non-lectin surface-
515 functionalized microparticles and 13.6 ± 1.9% higher for lectin surface-functionalized
516 microparticles. These data clearly suggest that the microparticles preserve the biological
517 activity of insulin in the systems tested.
 
518 Based on the parameter n calculated by fitting the release data into the Power law, the
519 average n value for the non-functionalized microparticles is 0.45 ± 0.06 (mean ± SD, n = 5)
520 and 0.36 ± 0.10 for lectin-functionalized microparticles in SIF. For a spherical system, when
521 n ≤ 0.43, the release mechanism is diffusion-controlled (Case I), whereas when n ≥ 0.85, the
522 release mechanism is swelling-controlled (Case II) and values between 0.43 and 0.89 present
523 a mixed mode of a both diffusion- and swelling-controlled mechanism (anomalous transport)
524 (Lin & Metters, 2006; Siepmann & Peppas, 2001). Thus, the release mechanism of insulin
525 from non-functionalized microparticles is of a mixed mode but is predominantly diffusion-
526 controlled, whereas for lectin-functionalized microparticles, it is diffusion-controlled.
 
527 Notably, the n value of fluorescein isothiocyanate (FITC)-labeled dextran (4.4 kDa)
528 (FD-4) encapsulated in the same carboxymethylated kappa-carrageenan microspheres in SIF
529 reported in our earlier study was 0.94 ± 0.03 (Leong et al., 2011). This result clearly suggests
530 that the release of FD-4 was purely swelling-controlled, whereas the release of insulin from
531 these microparticles in this study is predominantly under diffusion control. Unlike FD-4,
532 there are probably ionic interactions between the amino groups in the insulin molecule and
533 the sulfate groups of carboxymethylated kappa-carrageenan to impart diffusion-controlled
534 insulin release. This phenomenon also explains why the complete release of FD-4 in SIF took
535 2 h (Leong et al., 2011), whereas for the entrapped insulin in our study, the complete release
Page 25 of 43  
536 was extended to 6–8 h. Hence, the presence of sulfate groups in carboxymethylated kappa-
537 
 
 
538 
carrageenan imparts a sustained release property to entrapped insulin.
 
539 
 
 
540 
3.3.2 .Cell viability studies
 
541 To investigate the suitability of lectin-functionalized and non-functionalized
542 carboxymethylated kappa-carrageenan microparticles for insulin delivery purposes, both
543 MTS and LDH assays were carried out. The assays revealed that the microparticles at 0.5–10
544 mg/mL did not reduce the viability of Caco-2 cells to a significant level compared to the
545 untreated control (Figs. 5A & B). Microparticles at 20 mg/mL showed a reduction of cell
546 viability upon exposure to lectin-functionalized microparticles, from 106.8 ± 2.5 at day 1 to
547 95.3 ± 8.5 at day 2 and finally to 82.3 ± 11.5 at day 3. Other types of lectins showed a similar
548 reduction of cell viability upon longer exposure periods at such high concentrations
549 (Petrossian, Banner & Oppenheimer, 2007). However, lectins for drug targeting are normally
550 below the microgram range and are unlikely to provoke such effects (Gabor, Bogner,
551 Weissenboeck & Wirth, 2004). Moreover, the higher drug-loading capacity of our system
552 suggests that less carrier is required to deliver an equivalent amount of drug.
 
553 The intestinal membrane in humans provides a selective absorption of nutrients and
554 acts as a protective barrier against harmful foreign materials such as antigens, bacteria,
555 viruses and toxins. The intestine lining constitutes sheets of cells closely bound together, and
556 a tight junction is located in the intercellular space between cells (González-Mariscal, Nava
557 & Hernández, 2005). Because the opening of these tight junctions permits the invasion of
558 harmful substances (Khafagy, Morishita, Onuki & Takayama, 2007), it is pertinent to
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559 determine the effect of the drug carrier system against the integrity of tight junctions. Neither
560 lectin nor non-functionalized microparticles caused the opening of the tight junction, as
561 shown in Fig. 5C. There were no significant differences in the transepithelial electric
562 
 
 
563 
resistance (TEER) values of the samples, as compared to control (ANOVA, p > 0.05).
 
564 
 
 
565 
3.4. In vivo studies
 
566 Insulin entrapped in lectin-functionalized and non-functionalized carboxymethylated
567 kappa-carrageenan microparticles induced significant hypoglycemic effects on diabetic rats
568 (Figs. 6A & B). In contrast, the oral administration of human insulin (100 IU/mL), treatment
569 with capsules containing “empty” microparticles and lack of treatment did not induce a
570 significant hypoglycemic effect, and no detectable human insulin was found in the serum.
571 The observed level of the hypoglycemic response of insulin entrapped in microparticles is
572 related to the serum concentration of human insulin absorbed through the intestinal tract
573 (Figs. 6A & B), and is in turn correlated to the oral dose of insulin entrapped (25, 50 and 100
574 IU/mL) in the microparticles administered.
 
575 Insulin entrapped in lectin surface-functionalized carboxymethylated kappa-
576 carrageenan microparticles further increased and prolonged the hypoglycemic effect
577 compared to non-functionalized microparticles containing an equivalent amount of insulin.
578 This finding suggests that the grafting of lectin (wheat germ agglutinin; WGA) on the surface
579 of the microparticles improves the adhesive interactions of these microparticles with the
580 glycoconjugates present on the surface of the intestinal lining (Zhang, Ping, Huang & Xu,
581 2005; Zhang et al., 2006). The intimate contact of the microparticles creates a localized high
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582 gradient of insulin at the intestinal wall, which assists the absorption of insulin across the
583 intestinal wall into the systemic circulation.
 
584 Table 1 summarizes the pharmacokinetic parameters of orally administered insulin-
585 loaded microparticles and the subcutaneous injection of 2 IU insulin/kg. The area under the
586 plasma insulin concentration-time curve (AUC) for all of the formulations was calculated
587 over the experimental period of 36 h. The bioavailability was calculated relative to the
588 subcutaneous injection of 2 IU insulin/kg. The overall bioavailability of the lectin-
589 functionalized microparticles (12.8–14.8%) clearly outperformed that of the non-
590 functionalized microparticles (8.3–8.5%). The highest bioavailability obtained was 14.8 ±
591 0.7% for lectin-functionalized microparticles administered orally at 100 IU/kg, whereas non-
592 functionalized microparticles achieved 8.3 ± 0.1%. The serum insulin bioavailability of
593 lectin-functionalized microparticles at 50 IU/kg in this study (12.8%) is clearly higher than
594 similar lectin-functionalized oral carriers such as liposome-based (9.1%) (Zhang, Ping,
595 
 
 
596 
Huang & Xu, 2005) and lipid-based carriers (7.1%) (Zhang et al., 2006).
 
597 
 
 
598 
4. Conclusion
 
599 This study clearly shows that insulin entrapped in lectin-functionalized
600 carboxymethylated kappa-carrageenan microparticles was protected from hydrolysis and
601 proteolysis by stomach acids and enzymes. Grafting of lectin (WGA) on the surface of the
602 microparticles improves the interactions of these microparticles with the intestinal wall and
603 enhances the absorption of insulin compared to the non-functionalized microparticles. The
604 covalently bound, negatively charged sulfate groups (18.4% w/w) in carboxymethylated
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605 kappa-carrageenan interact with the amino groups of the amino acid residues in insulin via
606 ionic interactions that prevented the bulk release of insulin in the intestine, and these
607 interactions imparted a sustained release of up to 12–24 h for the insulin entrapped in the
608 microparticles compared to the rapid dissipation of the hypoglycemic effect of insulin via the
609 parenteral route. Therefore, this lectin-functionalized oral formulation might serve as a
610 promising alternative or as a complementary therapy to parenteral administration to provide a
611 
 
 
612 
better basal and prolonged hypoglycemic control.
 
613 
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Pharmacokinetics of various insulin formulations administered orally or subcutaneously to 
diabetic Sprague-Dawley rats
a
.
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Figure Captions
751 
 
752 
Fig. 1. HPLC profile of lectin (100 µg/mL) and human insulin (100 µg/mL).
753 Fig. 2. Preparation and characterization of insulin entrapped in lectin-functionalized
754 carboxymethylated kappa-carrageenan microparticles. (A) Encapsulation efficiency of insulin
755 
 
756 
using various polymer weights (125–175 mg) and needle sizes (0.4–0.5 mm). (B) Size of 
 
microparticles
a 
using various polymer weights (125–175 mg) and needle sizes (0.4–0.5 mm).
757 (C) The effect of pH on the encapsulation efficiency of insulin by the addition of 0.3 M
758 sodium acetate buffer into the insulin-polymer mixture. (D) Encapsulation efficiency of
759 insulin with increasing amounts of drug (10–35 mg).  (E) Percentage of insulin release in
760 simulated intestinal fluid (SIF) (pH 7.4) after crosslinking with polyglutaraldehyde (0.1–1.0%
761 v/v). (F) Percentage of microparticles by weight adhered to short segments (6 cm) of rat
762 
 
763 
intestine after lectin functionalization with increasing amount of lectin (0.25–1.25 mg). The 
results are expressed as the mean ± SD (n = 6) except 
a
(n = 50). 
b
Parameters selected for the
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764 fabrication of lectin-functionalized and non-functionalized microparticles for in vitro and in
765 
 
766 
vivo studies.
767 Fig. 3. Scanning electron micrographs (SEM) showing microparticles made from
768 encapsulating insulin in carboxymethylated kappa-carrageenan at (A) 50x and (B) 8000x
769 magnifications and lectin-functionalized microparticles made from insulin entrapped in
770 
 
771 
carboxymethylated kappa-carrageenan at (C) 50x and (D) 8000x magnifications.
772 Fig. 4. Dissolution profile of non-functionalized and lectin-functionalized carboxymethylated
773 kappa-carrageenan microparticles in simulated gastric fluid (SGF) at 37 ºC for 2 h, followed
774 by simulated intestinal fluid (SIF) at 37 ºC for 8 h. The results were expressed as the mean ±
775 
 
776 
SD (n = 6).
777 Fig. 5. (A) Cell viability (%) of human colon cells (Caco-2) measured using the MTS assay
778 after exposure to non-functionalized and lectin-functionalized carboxymethylated kappa-
779 carrageenan microparticles (0.5–20 mg/mL) over 1, 2 or 3 days. (B) Cell death (%) of Caco-2
780 cells measured using the LDH assay after exposure to non-functionalized and lectin-
781 functionalized carboxymethylated kappa-carrageenan microparticles (0.5–20 mg/mL) over 1,
782 
 
783 
2 or 3 days. The results were expressed as the mean ± SD (n = 6).
784 Fig. 6. (A) Hypoglycemia effect induced by various formulations after oral or subcutaneous
785 administration to diabetic Sprague-Dawley rats. The values were calculated as the percent
786 depression of blood glucose compared to the value before the start of the experiment. (B)
787 Serum human insulin levels of diabetic Sprague-Dawley rats after oral or subcutaneous
788 administration of various formulations. The results were expressed as the mean ± SD (n = 6).
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Table 1 
 
Pharmacokinetics of various insulin formulations administered orally or subcutaneously to diabetic Sprague-Dawley rats
a
. 
 
 
 
Formulations 
 
(dose administered) 
Cmax 
 
(mIU/L)
c
 
Tmax 
 
(h)
c
 
AUC0-36h 
 
(mIU h/L)
c
 
Relative 
 
bioavailability (%)
c
 
 
 
 
 
Subcutaneous injection (2 IU/kg) 
 
 
 
125.5 ± 6.1 
 
 
 
1 
 
 
 
210.9 ± 4.7 
 
 
 
100.0 
 
Lectin-funtionalized microparticles (25 IU/kg)
b
 
 
56.3 ± 3.8 
 
2 
 
376.5 ± 65.5 
 
14.3 ± 1.1 
Lectin-funtionalized microparticles (50 IU/kg)
b
 81.5 ± 6.7 2 666.9 ± 178.0 12.8 ± 1.5 
 
Lectin-funtionalized microparticles (100 IU/kg)
b
 
 
175.3 ± 25.4 
 
4 
 
1559.0 ± 174.6 
 
14.8 ± 0.7 
 
Non-funtionalized microparticles (50 IU/kg)
b
 
 
70.6 ± 13.4 
 
2 
 
446.2 ± 26.0 
 
8.5 ± 0.2 
 
Non-funtionalized microparticles (100 IU/kg)
b
 
 
114.1 ± 12.4 
 
4 
 
869.4 ± 22.8 
 
8.3 ± 0.1 
 
 
 
 
 
 
 
a 
The data were obtained from Fig. 6B.
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b 
Oral administration. 
 
 
c 
Each value represents the mean (± SD); n = 6.
 ' 
i 
Figure 1 
Click here to download high resolution image 
 
 
Fig. 1 
 
 
 
 
 
 
 
 
 
 
o ~                                                i  
 
o JO 
 
o 25-
 
 
110 
 
N 
2!>                                                                                                                                                                 
~
 
'"•
o I~ 
 
o let 
"5 
.5
 
o ~ 
o                                                                                                                                   
\ 
 
lItO              2-00                   300                 .00      500                  6.00                    7,00                 8 00 
 
 
 
 
 
 
 
 
 
 
 
Page 38 of43
 Figure 2A-F 
Click here to download high resolution image 
 
 Figure 3A-D 
Click here to download high resolution image 
 
 
 
 
 
 
A                                           B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c                            o 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 
 
 
 
Page 40 01'43
 - 
- ) 
- 
E     20 
> 
o 
-n:I 
80 
Figure 4 
Click here to download high resolution image 
 
 
Fig.4 
 
 
 
 
 
 
 
- 100   SGF                                    SIF 
CI 
 
Q) 
1/1 
n:I 
Q) 
Q... 
.c_   60 
::s 
.1_/1 
..
Q
.
)
.  
40
 
::s                                                                                • Non-functionalized 
::s                                                                                 • Lectin-functionalized 
 
0 
0          1        2         3         4         5         6         7         8         9         10 
 
Time (h) 
 
 
Page 41 of43
 Figure 5A-C 
Click here to download high resolution image 
 
 Figure 6A & B 
Click here to download high resolution image 
 
 
